Actualizado 05/06/2006 10:02
- Comunicado -

Results of Key Phase II Studies Demonstrate Progression Free Survival Advantage for ZD6474 (ZACTIMA) in Lung Cancer (y 2

2. Natale R et al. A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa(TM)) in patients with NSCLC: results of a randomized, double-blind Phase II study. Lung Cancer 2005; 49 (Suppl 2): S36.

3. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase N0.5. Lyon, IARC Press 2001

4. J. Ferlay, F. Bray, P. Pisani and D.M. Parkin. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide.

5. National Cancer Institute. Genetics of Medullary Thyroid Cancer. http://www.cancer.gov/cancertopics/pdq/g... sional. Last accessed 11 May 2006.

6. Gilliland FD, Hunt WC, Morris DM, Key CR (1997). Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973 - 1991. Cancer, 79: 564-573.

Janet Milton-Edwards, AstraZeneca, Tel: +44-1625-515-275, Mobile: +44-7990-640-119, janet.milton-edwards@astrazeneca.com; Odette England, AstraZeneca, Mobile: +44-7743-927-226, odette.england@astrazeneca.com

Contenido patrocinado